What is the appropriate acyclovir dosage for treating herpes simplex virus infection in an otherwise healthy adult?

Acyclovir Dosage for Herpes Treatment

For first-episode genital herpes in healthy adults, use acyclovir 200 mg orally 5 times daily for 7-10 days; for recurrent episodes, use 400 mg orally 3 times daily for 5 days or 800 mg orally twice daily for 5 days; and for severe disease requiring hospitalization, use 5-10 mg/kg IV every 8 hours for 5-7 days. 1, 2

Clinical Presentation-Based Dosing Algorithm

First Clinical Episode (Primary Infection)

• Standard genital herpes: Acyclovir 200 mg orally 5 times daily (every 4 hours while awake) for 7-10 days or until clinical resolution 3, 2
• Herpes proctitis: Acyclovir 400 mg orally 5 times daily for 10 days or until clinical resolution 3
• The 1998 CDC guidelines 1 maintain these same dosing recommendations, which have remained consistent across guideline iterations

Key consideration: Treatment initiated within the first 3 days of symptom onset provides the most benefit 4. The standard 200 mg dose 5 times daily is as effective as higher doses (4g daily) for first episodes, with the higher dose causing more gastrointestinal side effects 4.

Recurrent Episodes (Episodic Treatment)

Three equally effective options 1, 2:

• Acyclovir 200 mg orally 5 times daily for 5 days, OR
• Acyclovir 400 mg orally 3 times daily for 5 days, OR
• Acyclovir 800 mg orally twice daily for 5 days

Critical timing: Initiate therapy at the earliest sign of prodrome or within 1 day of lesion onset for maximum benefit 1. Provide patients with a prescription to keep on hand for immediate self-initiation 1.

The twice-daily 800 mg regimen offers superior convenience and compliance compared to the 5-times-daily regimen 5. A 2-day course (800 mg TID for 2 days) has also shown efficacy in reducing lesion duration and viral shedding 6, though this is not included in the primary guidelines.

Chronic Suppressive Therapy

For patients with ≥6 recurrences per year 3:

• Standard regimen: Acyclovir 400 mg orally twice daily 1, 2
• Alternative regimen: Acyclovir 200 mg orally 3-5 times daily (titrate to lowest effective dose) 3

Important management points:

• Suppressive therapy reduces recurrence frequency by ≥75% 1, 3
• Safety documented for up to 5-6 years of continuous use 3, 1
• Reassess after 1 year: Discontinue therapy temporarily to evaluate ongoing recurrence rate, as frequency naturally decreases over time in many patients 3, 1, 3, 1
• Does not eliminate asymptomatic viral shedding or completely prevent transmission 3, 1, 3

Severe Disease Requiring Hospitalization

For disseminated infection, encephalitis, pneumonitis, or hepatitis 1, 2:

• Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution 3, 1, 3, 1, 2

Special consideration for HSV-2 meningitis 7:

• First episode: Acyclovir 10 mg/kg IV every 8 hours until fever/headache resolve, then valacyclovir 1g TID to complete 14 days
• Recurrent episodes: May use oral therapy for entire course
• Critical distinction: HSV encephalitis requires 14-21 days of IV acyclovir due to high morbidity/mortality 7

Special Populations

HIV-Infected/Immunocompromised Patients

• Higher doses needed: Acyclovir 400 mg orally 3-5 times daily 1
• Prolonged treatment courses often required due to slower healing 1
• Monitor closely for acyclovir-resistant strains, particularly in advanced HIV 1
• Consider alternative agents (foscarnet, cidofovir) if resistance suspected 8

Renal Impairment

Dose adjustment required 2:

• CrCl >10 mL/min: Standard dosing
• CrCl 0-10 mL/min:
  • 200 mg dose: Give every 12 hours (instead of every 4 hours)
  • 400 mg dose: Reduce to 200 mg every 12 hours
  • 800 mg dose: Give every 12 hours (instead of every 4 hours)
• Hemodialysis: Administer additional dose after each dialysis session 2

Common Pitfalls and Caveats

Topical acyclovir is substantially less effective than oral therapy and should not be used 3. The systemic route is essential for adequate drug levels.

Resistance considerations: While acyclovir-resistant HSV strains have been isolated, they have not been associated with treatment failure in immunocompetent patients 3. However, in immunocompromised patients with poor clinical response, consider viral resistance testing and alternative agents 8.

Patient counseling essentials: Advise abstinence during active lesions, explain natural history including asymptomatic shedding and transmission risk, encourage condom use during all sexual activity, and discuss neonatal infection risks with women of childbearing age 3.

Subtherapeutic levels: In rare cases of treatment failure despite adequate dosing, consider checking acyclovir plasma levels; cimetidine co-administration may enhance systemic concentrations 9.